| Revenue growth | 23.9% YoY; 12.2% QoQ; record high |
|---|---|
| Margins | EBITDA margin 21.0%, up 75bps YoY, 45bps QoQ |
| Demand visibility | US ex-gRevlimid $477Mn, up 20% QoQ |
Growth
Revenue +23.9% YoY, +12.2% QoQ; EBITDA +28.5% YoY; PAT +32.5% YoY. US +25.2%, Europe +27.5% YoY.
Outlook
No numeric guidance. Omalizumab US FDA filing this FY; TheraNym Unit 1 qualification Mar 2027; Unit 2 (USD 180Mn capex) by 2030.
Risks
Tax outgo +31.8% YoY; Growth Markets -3.5% QoQ; ARV revenue tied to tender timing.
Investor Presentation filed with BSE, NSE: AUROPHARMA. Summary written with AI assistance from the document.
Aurobindo Pharma Ltd: key numbers
- Share price
- ₹1,705.00
- Market cap
- ₹99,027 Cr
- Revenue (annual)
- ₹33,653 Cr
- Net profit (annual)
- ₹3,505 Cr
- P/E (TTM)
- 25.1×Sector 37.9×
- Promoter holding
- 51.88%+0.00% QoQ
- FII holding
- 17.41%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Aurobindo Pharma Ltd
All →Aurobindo Pharma Acquisition Worth ₹29 Cr
Aurobindo's subsidiary Auropharm Overseas will buy 100% of Auro Pharma LLC, a Russian step-down subsidiary, for about Rs 29 crore cash. It is an internal group reorganisation.
- Value
- ₹29.00 Cr
- Execution
- 60-90 days
Aurobindo Pharma Management Change
Aurobindo Pharma's board approved reappointing independent director Mangalam Ramasubramanian Kumar for a second five-year term from April 1, 2027. Shareholder approval by postal ballot is required.
- Execution
- Five years from April 1, 2027
Aurobindo Pharma Merger & Restructuring Worth ₹29 Cr
Aurobindo Pharma approved transferring 100% of Auro Pharma LLC, Russia, between wholly owned subsidiaries. Cash consideration is about INR 29 crore, subject to adjustments.
- Value
- ₹29.00 Cr
- Execution
- 60-90 days
Aurobindo Pharma Acquisition
Aurobindo Pharma announced a board-approved proposal to merge two wholly owned subsidiaries, Auroactive Pharma into Apitoria Pharma, via NCLT scheme. No cash consideration; the share-exchange ratio issues 23,95,900 shares of Apitoria.
Aurobindo Pharma Dividend
Aurobindo Pharma declared an interim dividend of Rs 7.00 per share for FY27. Record date is 11 November 2026, with payment on or before 20 November.
Aurobindo Pharma Results Update
Aurobindo Pharma reported Q2 FY27 revenue of Rs.10,263 Crore, up 23.9% YoY, and net profit of Rs.1,124 Crore. An interim dividend of Rs.7 per share was declared.